NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants will have an exercise price of $1.75 per share and a three-year term. The closing is expected on or about May 18, 2026, subject to customary conditions. The full press release is available at https://ibn.fm/Z8Etj.
This capital raise is significant for NanoViricides as it continues to advance its clinical-stage, broad-spectrum antiviral drug NV-387. NV-387 has been granted Orphan Drug Designation (ODD) by the US FDA Office of Orphan Products Development (OOPD), which could provide 7 years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The company believes NV-387 could be a first-visit treatment for respiratory viral illnesses and has demonstrated effectiveness in lethal animal infection models against Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
The offering underscores investor confidence in NanoViricides' host-mimetic nanomedicine technology, which aims to create broad-spectrum antivirals that viruses and their variants cannot escape. The proceeds will likely support ongoing clinical trials and further development of NV-387. For more information about NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
